Physician profile
Todd W Morrison
NPI 1194751172
$3,527.51
in general payments reported to CMS, 2019-2025
37 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,315 · 2020: $124 · 2021: $264 · 2022: $250 · 2023: $540 · 2024: $592 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516 · Education: $57.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.35 |
| Education | $57.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.15 | 2021-2025 | |
| Novo Nordisk INC | $505.60 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $265.11 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Supernus Pharmaceuticals, INC. | $238.11 | 2019-2025 | Qelbree, Qelbree |
| Astrazeneca Pharmaceuticals LP | $208.08 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $197.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $177.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $157.23 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.77 | 2019-2024 | Trintellix |
| Amgen INC. | $116.69 | 2019-2025 | Repatha, Otezla, Repatha |
| Axsome Therapeutics, INC. | $84.14 | 2023-2025 | Auvelity, Sunosi |
| Krystal Biotech INC | $70.61 | 2023 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.73 | 2019-2024 | Jardiance |
| Corium, LLC | $61.01 | 2023-2024 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.53 | 2019-2024 | Xifaxan |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $47.50 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $42.93 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $38.18 | 2019 | |
| Ardelyx, INC. | $37.29 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $37.10 | 2019-2020 | |
| Cranial Technologies, INC | $33.25 | 2025 | Doc Band |
| Amneal Pharmaceuticals LLC | $31.23 | 2019-2024 | Unithroid |
| Horizon Therapeutics Plc | $29.88 | 2019 | |
| Chiesi USA, INC. | $28.97 | 2025 | Filsuvez |
| Medtronic Minimed, INC. | $23.16 | 2019 | |
| Abbott Laboratories | $21.50 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $21.42 | 2024 | Rexulti |
| Dexcom, INC. | $20.98 | 2023 | Dexcom G6 Transmitter |
| Upsher-Smith Laboratories LLC | $20.22 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.96 | 2024 | Caplyta |
| Eisai INC. | $17.36 | 2020 | |
| Antares Pharma, INC. | $15.43 | 2019 | |
| Shire North American Group INC | $13.80 | 2019 | |
| Cequr Corporation | $13.17 | 2024 | Cequr Simplicity |
| Ironshore Pharmaceuticals INC. | $12.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.27 | 2019 | |
| Sanofi Pasteur INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.